Next Article in Journal
Metformin Alleviates Obesity and Systemic Oxidative Stress in Obese Young Swine
Previous Article in Journal
Approaches to Manipulate Ephrin-A:EphA Forward Signaling Pathway
Previous Article in Special Issue
Physicochemical Investigation of Psoralen Binding to Double Stranded DNA through Electroanalytical and Cheminformatic Approaches
Open AccessArticle

Computer-Aided Design, Synthesis, and Antiviral Evaluation of Novel Acrylamides as Potential Inhibitors of E3-E2-E1 Glycoproteins Complex from Chikungunya Virus

1
Laboratory of Medicinal Chemistry, Pharmaceutical Sciences Institute, Federal University of Alagoas, Maceió 57072-970, Brazil
2
Center of Analysis and Research in Nuclear Magnetic Resonance, Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió 57072-970, Brazil
3
Immunoregulation Research Group, Laboratory of Research in Virology and Immunology, Institute of Biological and Health Sciences, Federal University of Alagoas, Maceió 57072-970, Brazil
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(7), 141; https://doi.org/10.3390/ph13070141
Received: 31 May 2020 / Revised: 23 June 2020 / Accepted: 25 June 2020 / Published: 30 June 2020
Chikungunya virus (CHIKV) causes an infectious disease characterized by inflammation and pain of the musculoskeletal tissues accompanied by swelling in the joints and cartilage damage. Currently, there are no licensed vaccines or chemotherapeutic agents to prevent or treat CHIKV infections. In this context, our research aimed to explore the potential in vitro anti-CHIKV activity of acrylamide derivatives. In silico methods were applied to 132 Michael’s acceptors toward the six most important biological targets from CHIKV. Subsequently, the ten most promising acrylamides were selected and synthesized. From the cytotoxicity MTT assay, we verified that LQM330, 334, and 336 demonstrate high cell viability at 40 µM. Moreover, these derivatives exhibited anti-CHIKV activities, highlighting the compound LQM334 which exhibited an inhibition value of 81%. Thus, docking simulations were performed to suggest a potential CHIKV-target for LQM334. It was observed that the LQM334 has a high affinity towards the E3-E2-E1 glycoproteins complex. Moreover, LQM334 reduced the percentage of CHIKV-positive cells from 74.07 to 0.88%, 48h post-treatment on intracellular flow cytometry staining. In conclusion, all virtual simulations corroborated with experimental results, and LQM334 could be used as a promising anti-CHIKV scaffold for designing new drugs in the future. View Full-Text
Keywords: virtual screening; acrylamides; chikungunya virus; antiviral; molecular docking; E3-E2-E1 glycoproteins complex virtual screening; acrylamides; chikungunya virus; antiviral; molecular docking; E3-E2-E1 glycoproteins complex
Show Figures

Graphical abstract

MDPI and ACS Style

Passos, G.F.S.; Gomes, M.G.M.; Aquino, T.M.; Araújo-Júnior, J.X.; Souza, S.J.M.; Cavalcante, J.P.M.; Santos, E.C.; Bassi, Ê.J.; Silva-Júnior, E.F. Computer-Aided Design, Synthesis, and Antiviral Evaluation of Novel Acrylamides as Potential Inhibitors of E3-E2-E1 Glycoproteins Complex from Chikungunya Virus. Pharmaceuticals 2020, 13, 141.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop